
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Out-of-the-box usability of Thermo Scientific™ UltiMate™ 3000 and Vanquish Core HPLC instruments for the compendial analysis of commonly prescribed drugs.





